MABTHERA 1400 mg, solution for injection subcutaneous bottle

Telegram WhatsApp

Link to share

Active ingredients: Rituximab

Commercialized according to BDPMDispensing in France: Prescription only

Solution for injectionbottlesous-cutanée

No current ANSM shortage notice is included

Package details

Original BDPM fields are shown in French.

Official name: MABTHERA 1400 mg, solution pour injection sous-cutanée
Pharmaceutical form: solution injectable
Route of administration: sous-cutanée
Presentation description: 1 flacon(s) en verre
Marketing authorisation holder: ROCHE REGISTRATION (ALLEMAGNE)
Reimbursement according to BDPM: —
Approval for use in healthcare institutions: oui
Commercialization declaration date: 22 Jun 2015
Prescription and dispensing conditions: Prescription only
List I: prescription-only medicine
Requires special monitoring during treatment
Prescribed by a hospital doctor
Prescribed by specialists only
Original BDPM wording: la première administration doit être effectuée en milieu hospitalier · liste I · médicament nécessitant une surveillance particulière pendant le traitement · prescription hospitalière · prescription réservée aux médecins compétents en maladie du sang · prescription réservée aux spécialistes et services HEMATOLOGIE
Enhanced ANSM monitoring: No

BDPM identifiers

CIS65314657CIP75865992CIP133400958659928

Composition in BDPM

Composition in BDPM
Component	Amount per unit	Source type
RITUXIMABsolution	1400 mg · un flacon	SA

Information is based on BDPM data and is for reference only. Consult a doctor before use.

Similar medicines

Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.

The current BDPM data does not list similar medicines for this product.